ARTICLE | Clinical News
CCX168: Phase II data
August 8, 2016 7:00 AM UTC
Top-line data from the double-blind, placebo-controlled, North American Phase II CLASSIC trial in 42 patients with newly diagnosed or relapsed AAV showed that twice-daily 10 and 30 mg CCX168 plus stan...